Fractyl Health announced on September 26, 2025, groundbreaking results from the REMAIN-1 Midpoint Cohort, supporting Revita's potential as the first therapy to preserve weight loss after GLP-1 drug discontinuation. The pilot study met its key 3-month efficacy endpoint with strong statistical significance (p=0.014).
Revita-treated patients lost an additional 2.5% total body weight after stopping tirzepatide, while sham patients regained 10% at 3 months. This clinically and statistically significant difference provides randomized, blinded evidence that drug-free, durable weight maintenance is possible.
The Revita procedure demonstrated excellent safety and tolerability, consistent with prior clinical studies. These results validate the pivotal study design and reinforce Revita’s potential to be a first-in-class treatment in a new therapeutic category for post-GLP-1 weight maintenance. The REMAIN-1 Midpoint Cohort is ongoing, with 6-month randomized data expected in Q1 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.